Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 19/11/2012 18680_de.jpg

    Uncovering the genetics of prostate cancer

    The prostate genome project, which is part of the International Cancer Genome Consortium, is focused on the genetic and epigenetic causes of the development and progression of this highly variable cancer and finding markers that enable the reliable diagnosis of the disease. The German research groups involved in the project are coordinated by the German Cancer Research Center and concentrate on prostate cancer patients under 50 years of age, as…

    https://www.gesundheitsindustrie-bw.de/en/article/news/uncovering-the-genetics-of-prostate-cancer
  • Press release - 14/01/2008

    Prostate cancer: Improving the success of treatment

    Prostate cancer is the most frequent malignant tumour in men. Researchers from Freiburg and Bonn have succeeded in developing the basics for new therapies in particular for the treatment of advanced prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-improving-the-success-of-treatment
  • Press release - 10/12/2008

    CureVac to Start First mRNA Vaccine Clinical Trial in Prostate Cancer

    The German regulatory authority has approved the Clinical Trial Application CTA to begin a Phase I clinical study with RNActive - derived mRNA vaccine CV9103. It will be tested in patients with hormone-refractory metastatic prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-to-start-first-mrna-vaccine-clinical-trial-in-prostate-cancer
  • Article - 13/09/2010 12377_de.jpg

    Sven Perner: a pathologist with the courage to carry out interdisciplinary research

    Dr Sven Perner from Tuebingen was recently awarded the newly created Württemberg Cancer Prize for his work that has made decisive contributions to the understanding of prostate cancer development. In addition the identification of a tumour-specific gene fusion might also be of great importance for other types of cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/sven-perner-a-pathologist-with-the-courage-to-carry-out-interdisciplinary-research
  • Article - 26/01/2015 22698_de.jpg

    A biomarker as indicator for the likelihood of developing aggressive prostate cancer

    Overexpression of the protein BAZ2A, which leads to alterations in epigenetic patterns, increases the malignant properties of tumour cells, including their mobility and their ability to form metastases. The findings of a team of researchers from Heidelberg, Zurich and Hamburg may have led to the discovery of an urgently needed prognostic biomarker that would make it possible to differentiate aggressive prostate cancer from the less malignant…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-biomarker-as-indicator-for-the-likelihood-of-developing-aggressive-prostate-cancer
  • Article - 04/03/2013 19277_de.jpg

    Genomic structural variations can cause cancer

    Genome-wide sequencing analyses show that comprehensive structural variations of chromosomes can play a key role in the pathogenesis of many types of cancer. Dr. Jan Korbel’s research group at the European Molecular Biology Laboratory in Heidelberg has been investigating chromosomal aberrations in paediatric brain tumours and early-onset prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/genomic-structural-variations-can-cause-cancer
  • Press release - 26/01/2011

    Uncovering the Genetics of Prostate Cancer

    Germany will contribute another project to the International Cancer Genome Consortium ICGC. Coordinated by the German Cancer Research Center and the University Medical Center Hamburg-Eppendorf physicians and molecular biologists will now start to investigate the genetic causes of early prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/uncovering-the-genetics-of-prostate-cancer-1
  • Article - 14/09/2022 Radiodiagnostik von Prostatakrebs durch Positronen-Emissions-Tomografie

    Theranostics of prostate cancer: the combination of radionuclide diagnostics and radionuclide therapy

    Using a low-level radiopharmaceutical that binds to the prostate-specific membrane antigen (PSMA), positron emission tomography/computed tomography can be used to visualise even small prostate cancer metastases. Developed by Heidelberg researchers, the radiopharmaceutical is a modified radionuclide diagnostic agent that has been coupled with a powerful emitter and used as a therapeutic tracer to irradiate and destroy cancer cells from within.

    https://www.gesundheitsindustrie-bw.de/en/article/news/theranostics-prostate-cancer-combination-radionuclide-diagnostics-and-radionuclide-therapy
  • Press release - 14/01/2009

    IND Approval for CureVac

    CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ind-approval-for-curevac
  • Press release - 04/11/2009

    CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

    CureVac GmbH, the mRNA vaccine company, today announced that the German authorities approved the start of the Phase IIa trial in Prostate Cancer after assessment of the first safety data of lead candidate CV9103, a RNActive®-derived mRNA vaccine. Results so far from the Phase I show CV9103 to be safe and well tolerated.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-launches-phase-iia-mrna-vaccine-trial-in-prostate-cancer
  • Press release - 01/04/2022

    FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer

    On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
  • Press release - 14/12/2022

    New drug for metastatic prostate cancer now also approved in Europe

    On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neues-medikament-gegen-metastasierten-prostatakrebs-nun-auch-europa-zugelassen
  • Article - 05/06/2008

    CureVac: partnership with University of Florida,

    CureVac GmbH has entered into a partnership with the Department of Urology University of Florida Gainesville U.S. to jointly advance its lead candidate CV9103 into the clinical development. The alliance covers preclinical studies and a US phase III trial.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-partnership-with-university-of-florida
  • Press release - 20/06/2011 07777_de.jpg

    CureVac presents new data for prostate and lung cancer vaccines

    CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
  • Dossier - 12/12/2011 16006_de.jpg

    Development of new molecular biomarkers

    Biomarkers are playing an increasing role in drug discovery and development. They can be used as molecular indicators for diseases and disease risks as well as for monitoring the effectiveness of therapy. Highly specific molecular biomarkers are being identified using state-of-the-art technologies from the fields of genomics, proteomics and metabolomics.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/development-of-new-molecular-biomarkers
  • Press release - 12/05/2010 07777_de.jpg

    CureVac raises EUR 27.6 Million in Financing Round

    CureVac GmbH, the mRNA vaccine company, today announced the closing of a EUR 27.6 million (US$ 35.25 million) financing round with its major shareholder, dievini Hopp BioTech holding GmbH & Co. KG.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-eur-27-6-million-in-financing-round
  • Press release - 12/11/2012 16634_de.jpg

    Searching for new strategies against prostate cancer

    The European Research Council (ERC) has announced that Roland Schüle, Scientific Director at the Department of Urology, University of Freiburg Medical Centre has been awarded an ERC Advanced Grant. Professor Schüle will receive €2.5 million for a period of 5 years for his research proposal to identify and characterize the molecular and physiological functions of the epigenetic enzyme LSD1 and to explore its role in prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/searching-for-new-strategies-against-prostate-cancer
  • Press release - 22/11/2012 18767_de.jpg

    CeGaT and Genomatix are finalists of Boston Children’s Hospital’s CLARITY challenge

    CeGaT (Center for Genomics and Transcriptomics) GmbH, the Department of Prostate Cancer Research, Institute of Pathology, University Hospital Bonn and Genomatix Software GmbH were announced as finalist (Top 3) of the CLARITY challenge, organized by Boston Children’s Hospital.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-and-genomatix-are-finalists-of-boston-children-s-hospital-s-clarity-challenge
  • Press release - 20/01/2023

    Czech Inventor Award for Martina Benešová-Schäfer

    With the "Česká Hlava" awards, the Czech government has been honoring the country's most brilliant minds every year since 2002 and recognizing exceptional achievements in research, development and innovation. Martina Benešová-Schäfer of the German Cancer Research Center was among the six laureates honored in 2022 at Charles University in Prague.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tschechischer-erfinderpreis-fuer-martina-benesova-schaefer
  • Article - 16/04/2008

    Roland Schuele - "Research cannot be predicted"

    Professor Roland Schuele from the University Womens Hospital in Freiburg originally studied biochemistry. Nowadays Schuele is researching the development of prostate cancer. During his scientific career he has learnt that research cannot be steered in a particular direction. It develops and we follow it said Schuele who has been able to gain astonishing insights into the molecular processes in tumour cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/roland-schuele-research-cannot-be-predicted
  • Article - 18/01/2018 Teaser-Mutationen-Primartumor.png

    Medications that target metastasing tumours

    Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
  • Press release - 22/06/2010

    CureVac starts Phase IIa with mRNA immunotherapeutic in Non-Small Cell Lung Cancer

    CureVac GmbH, the mRNA company, today announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the start of a Phase IIa trial for CV9201 to treat Non-Small Cell Lung Cancer (NSCLC).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-starts-phase-iia-with-mrna-immunotherapeutic-in-non-small-cell-lung-cancer
  • Press release - 22/06/2009 Green fluorescent cells - on the left with cell extensions, on the right rather rounded.

    New important triggers for the migration of cancer cells

    Embryonic cells and metastasising cancer cells are able to migrate and intrude into other tissues. Investigations of frog embryos have now provided scientists at the Karlsruhe Institute of Technology with the information that a well-known protein, cadherin-11, triggers cell migration. This glycoprotein is also responsible for the defective behaviour of cells that results in prostate cancer and arthritis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-important-triggers-for-the-migration-of-cancer-cells
  • Press release - 28/05/2009 07777_de.jpg

    CureVac Begins Clinical Study with mRNA Vaccine

    CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-begins-clinical-study-with-mrna-vaccine
  • Press release - 09/03/2011 13866_de.jpg

    DKFZ and IBM have signed a collaboration agreement on cancer genome analysis

    The International Cancer Genome Project analyzes the complete genomes of thousands of cancer patients. This generates enormous amounts of data. To find those gene segments which are pivotal for cancer development and treatment, intelligent IT systems are needed. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg and IBM have signed a strategic partnering agreement at CeBIT 2011. The aim of the agreement is to…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-ibm-have-signed-a-collaboration-agreement-on-cancer-genome-analysis

Page 1 / 2

sb_search.block.search_result.other.pages

  • 1
  • 2
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search